- Home
- PNF vs CTSO Comparison
PNF vs CTSO Comparison
Compare PNF & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNF
- CTSO
- Stock Information
- Founded
- PNF 2001
- CTSO 1997
- Country
- PNF United States
- CTSO United States
- Employees
- PNF N/A
- CTSO N/A
- Industry
- PNF Finance Companies
- CTSO Medical/Dental Instruments
- Sector
- PNF Finance
- CTSO Health Care
- Exchange
- PNF Nasdaq
- CTSO Nasdaq
- Market Cap
- PNF 54.9M
- CTSO 52.6M
- IPO Year
- PNF N/A
- CTSO N/A
- Fundamental
- Price
- PNF $6.94
- CTSO $1.19
- Analyst Decision
- PNF
- CTSO Buy
- Analyst Count
- PNF 0
- CTSO 2
- Target Price
- PNF N/A
- CTSO $5.50
- AVG Volume (30 Days)
- PNF 29.1K
- CTSO 107.9K
- Earning Date
- PNF 01-01-0001
- CTSO 08-12-2025
- Dividend Yield
- PNF 5.17%
- CTSO N/A
- EPS Growth
- PNF N/A
- CTSO N/A
- EPS
- PNF N/A
- CTSO N/A
- Revenue
- PNF N/A
- CTSO $35,332,238.00
- Revenue This Year
- PNF N/A
- CTSO $18.34
- Revenue Next Year
- PNF N/A
- CTSO $19.82
- P/E Ratio
- PNF N/A
- CTSO N/A
- Revenue Growth
- PNF N/A
- CTSO 15.37
- 52 Week Low
- PNF $6.37
- CTSO $0.70
- 52 Week High
- PNF $9.06
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- PNF 47.36
- CTSO 54.48
- Support Level
- PNF $6.89
- CTSO $1.12
- Resistance Level
- PNF $7.02
- CTSO $1.39
- Average True Range (ATR)
- PNF 0.07
- CTSO 0.11
- MACD
- PNF 0.01
- CTSO 0.01
- Stochastic Oscillator
- PNF 52.24
- CTSO 31.71
About PNF PIMCO New York Municipal Income Fund
PIMCO New York Municipal Income Fund is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund's portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.